Previously treated metastatic TNBC and HR positive HER2 negative breast cancer, germline BRCA 1/2 mutatedvelaparib+paclitaxel/carboplatin vs.placebo+paclitaxel/carboplatin. Here, ERBB2 is linked to breast cancer.